Discovery and Development of Small Molecule SHIP Phosphatase Modulators

Medicinal Research Reviews

Volumn 34, Issue 4, 2014, Pages 795-824

  Viernes, Dennis R ^a   Choi, Lydia B ^a   Kerr, William G ^a,b   Chisholm, John D ^a  

^a SYRACUSE UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Drug development; Enzyme agonist; Enzyme inhibition; Inositol phosphatase; PI3K; SHIP

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SESQUITERPINE PELOROL; SRC HOMOLOGY 2 CONTAINING INOSITOL 5 PHOSPHATASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; MOLECULAR LIBRARY; PHOSPHATASE;

ALZHEIMER DISEASE; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; FOLLOW UP; HEART GRAFT; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; INFLAMMATORY DISEASE; MORTALITY; NEOPLASM; NEUTROPENIA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASES; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY;

ANIMALS; DISEASE; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84901846034     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21305     Document Type: Article

References (154)

1. Ooms LM, Horan KA, Rahman P, Seaton G, Gurung R, Kethesparan DS, Mitchell CA. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem J 2009;419:29-49.
2. Dyson JM, Fedele CG, Davies EM, Becanovic J, Mitchell CA. Phosphoinositide phosphatases: Just as important as the kinases. Subcell Biochem 2012;58:215-279.
3. Bunney TD, Katan M. Phosphoinositide signalling in cancer: Beyond PI3K and PTEN. Nat Rev Cancer 2010;10:342-352.
4. Elong Edimo W, Janssens V, Waelkens E, Erneux C. Reversible Ser/Thr SHIP phosphorylation: A new paradigm in phosphoinositide signalling? Targeting of SHIP1/2 phosphatases may be controlled by phosphorylation on Ser and Thr residues. BioEssays 2012;34:634-642.
5. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-644.
6. Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev 2012;64:1027-1054.
7. Blunt MD, Ward SG. Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: Success, disappointment, and new opportunities. Front Immunol 2012;3: 226.
8. Suwa A, Kurama T, Shimokawa T. SHIP2 and its involvement in various diseases. Expert Opin Ther Targets 2010;14:727-737.
9. Hamilton MJ, Ho VW, Kuroda E, Ruschmann J, Antignano F, Lam V, Krystal G. Role of SHIP in cancer. Exp Hematol 2011;39:2-13.
10. Fernandes S, Iyer S, Kerr WG. Role of SHIP1 in cancer and mucosal inflammation. Ann NY Acad Sci 2013;1280:6-10.
11. Kerr WG. Inhibitor and activator: Dual functions for SHIP in immunity and cancer. Ann NY Acad Sci 2011;1217:1-17.
12. Iyer S, Margulies BS, Kerr WG. Role of SHIP1 in bone biology. Ann NY Acad Sci 2013;1280:11-14.
13. Zhang X, Majerus PW. Phosphatidylinositol signaling reactions. Semin Cell Dev Biol 1998;9:153-160.
14. 3 interactome. J Proteome Res 2009;8:3712-3726.
15. Cantley LC. The phosphoinositide-3-kinase pathway. Science 2002;296:1655-1657.
16. Marion F, Williams DE, Patrick BO, Hollander I, Mallon R, Kim SC, Roll DM, Feldberg L, Van Soest R, Andersen RJ. Liphagal, a Selective inhibitor of PI3 kinase a isolated from the sponge akacoralliphaga: Structure elucidation and biomimetic synthesis. Org Lett 2006;8:321-324.
17. Zhang H, He J, Kutateladze TG, Sakai T, Sasaki T, Markadieu N, Erneux C, Prestwich GD. 5-Stabilized phosphatidylinositol 3, 4, 5-trisphosphate analogues bind Grp1 PH, inhibit phosphoinositide phosphatases, and block neutrophil migration. Chembiochem 2010;11:388-395.
18. Leslie NR, Biondi RM, Alessi DR. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem Rev 2001;101:2365-2380.
19. Krystal G. Lipid phosphatases in the immune system. Semin Immunol 2000;12:397-403.
20. Sewell GW, Marks DJ, Segal AW. The immunopathogenesis of Crohn's disease: A three-stage model. Curr Opin Immunol 2009;21:506-513.
21. Veillette A, Latour S, Davidson D. Negative regulation of immunoreceptor signaling. Annu Rev Immunol 2002;20:669-707.
22. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, Moodie S, Stokoe D. 5′ Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 2000;20:6860-6871.
23. Kerr WG. A role for SHIP in stem cell biology and transplantation. Curr Stem Cell Res Ther 2008;3:99-106.
24. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 1997;275:665-668.
25. Ma K, Cheung SM, Marshall AJ, Duronio V. PI(3, 4, 5)P3 and PI(3, 4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3, 4)P2 levels determine PKB activity. Cell Signal 2008;20:684-694.
26. Brooks R, Fuhler GM, Iyer S, Smith MJ, Park MY, Paraiso KH, Engelman RW, Kerr WG. SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J Immunol 2010;184:3582-3589.
27. Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG. Therapeutic potential of SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med 2012;18:65-75.
28. Krystal G, Damen JE, Helgason CD, Huber M, Hughes MR, Kalesnikoff J, Lam V, Rosten P, Ware MD, Yew S, Humphries RK. Ships ahoy. Int J Biochem Cell Biol 1999;31:1007-1010.
29. Erneux C, Govaerts C, Communi D, Pesesse X. The diversity and possible functions of the inositol polyphosphate 5-phosphatases. Biochim Biophys Acta 1998;1436:185-199.
30. Hazen AL, Smith MJ, Desponts C, Winter O, Moser K, Kerr WG. SHIP is required for a functional hematopoietic stem cell niche. Blood 2009;113:2924-2933.
31. Pesesse X, Deleu S, De Smedt F, Drayer L, Erneux C. Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem Biophys Res Commun 1997;239:697-700.
32. Zhang Y, Wavreille AS, Kunys AR, Pei D. The SH2 domains of inositol polyphosphate 5-phosphatases SHIP1 and SHIP2 have similar ligand specificity but different binding kinetics. Biochemistry 2009;48:11075-11083.
33. Miletic AV, Anzelon-Mills AN, Mills DM, Omori SA, Pedersen IM, Shin D-M, Ravetch JV, Bolland S, Morse HC, III, Rickert RC. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med 2010;207:2407-2420.
34. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G, Humphries RK. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998;12:1610-1620.
35. Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, Pesesse X, Sasaki T, Penninger J, Doherty M, Malaisse W, Dumont JE, Le Marchand-Brustel Y, Erneux C, Hue L, Schurmans S. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001;409:92-97.
36. Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, Kline WO, Garcia K, Stitt TN, Yancopoulos GD, Wiegand SJ, Glass DJ. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 2005;11:199-205.
37. Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, Rickert RC, Gronbaek K, David M. Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas. EMBO Mol Med 2009;1:288-295.
38. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009;106:7113-7118.
39. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, Bueso-Ramos CE, Corey SJ. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene 2012;31:4085-4094.
40. 2 production, and intrinsic docking properties. J Cell Biochem 2011;112:2203-2209.
41. 2 and does it signal independently of its phosphatase activity? BioEssays 2013;35:733-743.
42. Wahle JA, Paraiso KH, Kendig RD, Lawrence HR, Chen L, Wu J, Kerr WG. Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J Immunol 2007;179:8009-8015.
43. Peng Q, Malhotra S, Torchia J, Kerr WG, Coggeshall KM, Humphrey MB. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal 2010;3:ra38.
44. Wu P, Hu Y. Small molecules targeting phosphoinositide 3-kinases. MedChemComm 2012;3:1337-1355.
45. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase-Moving towards therapy. Biochim Biophys Acta 2008;1784:159-185.
46. Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors: Addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol 2012;30:331-333.
47. Ciraolo E, Morello F, Hirsch E. Present and future of PI3K pathway inhibition in cancer: Perspectives and limitations. Curr Med Chem 2011;18:2674-2685.
48. Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 1996;88:1542-1550.
49. Inoki K, Li Y, Zhu T, Wu J, Guan K-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-657.
50. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
51. Peso Ld, González-García M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-689.
52. Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 2006;281:813-823.
53. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395.
54. Zhang X, Jin B, Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 2007;7:305-316.
55. Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, Berenson JR. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 2006;25:6520-6527.
56. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011;13:224-236.
57. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006;13:137-144.
58. Alkan S, Izban KF. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 2002;99:2278-2279.
59. Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Modern Path 2010;23:27-37.
60. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;70:4151-4162.
61. Montero JC, Lopez-Perez R, San Miguel JF, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: Differences in signaling and drug sensitivity. Haematologica 2008;93:851-859.
62. Harvey RD, Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 2007;3:639-647.
63. Berardi DE, Campodónico PB, Bessone MID, Urtreger AJ, Todaro LB. Autophagy: Friend or foe in breast cancer development, progression, and treatment. Int J Breast Cancer 2011;2011:595092.
64. Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of macroautophagy regulation in mammalian cells. Cell Res 2010;20:748-762.
65. Moretti L, Yang ES, Kim KW, Lu B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist Updat 2007;10:135-143.
66. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010;9:3470-3478.
67. O'Donovan TR, O'Sullivan GC, McKenna S. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011;7:509-524.
68. Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang Y, Dong B, Chen X. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res 2011;17:6229-6238.
69. Brauer H, Strauss J, Wegner W, Mueller-Tidow C, Horstmann M, Juecker M. Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling. Cell Signal 2012;24:2095-2101.
70. Lakhanpal GK, Vecchiarelli-Federico LM, Li Y-J, Cui J-W, Bailey ML, Spaner DE, Dumont DJ, Barber DL, Ben-David Y. The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. Blood 2010;116:428-436.
71. Kennah M, Yau TY, Nodwell M, Krystal G, Anderson RJ, Ong CJ, Mui AL. Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Exp Hematol 2009;37:1274-1283.
72. Prasad NK, Decker SJ. SH2-containing 5′-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 2005;280:13129-13136.
73. Prasad NK, Tandon M, Badve S, Snyder PW, Nakshatri H. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 2008;29:25-34.
74. Prasad NK, Tandon M, Handa A, Moore GE, Babbs CF, Snyder PW, Bose S. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumor Biol 2008;29:330-341.
75. Prasad NK. SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells. Int J Oncol 2009;34:97-105.
76. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010;11:9-22.
77. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475-482.
78. Wang J-W, Howson JM, Ghansah T, Desponts C, Ninos JM, May SL, Nguyen KHT, Toyama-Sorimachi N, Kerr WG. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002;295:2094-2097.
79. Karlsson MC, Guinamard R, Bolland S, Sankala M, Steinman RM, Ravetch JV. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med 2003;198:333-340.
80. Liu Q, Sasaki T, Kozieradzki I, Wakeham A, Itie A, Dumont DJ, Penninger JM. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 1999;13:786-791.
81. Ivetac I, Gurung R, Hakim S, Horan KA, Sheffield DA, Binge LC, Majerus PW, Tiganis T, Mitchell CA. Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. EMBO Rep 2009;10:487-493.
82. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009;16:115-125.
83. Fedelea CG, Oomsa LM, Hoa M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, Giles GG, Bailey CG, Rasko JEJ, Shields BJ, Price JT, Majerus PW, Sutherland RL, Tiganis T, McLean CA, Mitchell CA. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 2010;107:22231-22236.
84. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: The new kid on the PI3K block. Oncotarget 2011;2:321-328.
85. Baran CP, Tridandapani S, Helgason CD, Humphries RK, Krystal G, Marsh CB. The inositol 5′-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem 2003;278:38628-38636.
86. Freeburn RW, Wright KL, Burgess SJ, Astoul E, Cantrell DA, Ward SG. Evidence that SHIP1 contributes to phosphatidylinositol 3, 4, 5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol 2002;169:5441-5450.
87. Horn S, Endl E, Fehse B, Weck MM, Mayr GW, Jücker M. Restoration of SHIP1 activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3b signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 2004;18:1839-1849.
88. Haddon DJ, Antignano F, Hughes MR, Blanchet M-R, Zbytnuik L, Krystal G, McNagny KM. SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo. J Immunol 2009;183:228-236.
89. Strassheim D, Kim JY, Park JS, Mitra S, Abraham E. Involvement of SHIP in TLR2-induced neutrophil activation and acute lung injury. J Immunol 2005;174:8064-8071.
90. Kerr WG, Park MY, Maubert M, Engelman RW. SHIP deficiency causes Crohn's disease-like ileitis. Gut 2011;60:177-188.
91. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-962.
92. Shenker BJ, Dlakic M, Walker LP, Besack D, Jaffe E, LaBelle E, Boesze-Battaglia K. A novel mode of action for a microbial-derived immunotoxin: The cytolethal distending toxin subunit B exhibits phosphatidyl 3, 4, 5-triphosphate phosphatase activity. J Immunol 2007;178:5099-5108.
93. Ghansah T, Paraiso KH, Highfill S, Desponts C, May S, McIntosh JK, Wang JW, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr WG. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol 2004;173:7324-7330.
94. Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol 2007;178:2893-2900.
95. + T cells by semiprofessional antigen-presenting cells in vivo. J Exp Med 1992;176:1291-1302.
96. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-415.
97. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, Ferrara JL. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002;8:575-581.
98. + cells. J Immunol 1998;161:5313-5320.
99. Wahle JA, Paraiso KH, Costello AL, Goll EL, Sentman CL, Kerr WG. Cutting edge: Dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol 2006;176:7165-7169.
100. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399.
101. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-1150.
102. + regulatory T cells protects from lethal acute GVHD. Blood 2005;105:2220-2226.
103. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, June CH, Serody JS, Blazar BR. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004;104:3804-3812.
104. Collazo MM, Wood D, Paraiso KH, Lund E, Engelman RW, Le CT, Stauch D, Kotsch K, Kerr WG. SHIP limits immunoregulatory capacity in the T-cell compartment. Blood 2009;113:2934-2944.
105. Collazo MM, Paraiso KH, Park MY, Hazen AL, Kerr WG. Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP. Eur J Immunol 2012;42:1785-1795.
106. Murphy WJ, Kumar V, Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 1987;166:1499-1509.
107. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-1150.
108. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499.
109. Xiao M, Whitnall MH. Pharmacological countermeasures for the acute radiation syndrome. Curr Mol Pharmacol 2009;2:122-133.
110. Donnelly EH, Nemhauser JB, Smith JM, Kazzi ZN, Farfán EB, Chang AS, Naeem SF. Acute radiation syndrome: Assessment and management. South Med J 2010;103:541-544.
111. Iyer S, Kerr WG. Unpublished results.
112. Tu Z, Ninos JM, Ma Z, Wang J-W, Lemos MP, Desponts C, Ghansah T, Howson JM, Kerr WG. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein. Blood 2001;98:2028-2038.
113. Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, Kurama T, Shimokawa T, Aramori I. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br J Pharmacol 2009;158:879-887.
114. Ishihara H, Sasaoka T, Hori H, Wada T, Hirai H, Haruta T, Langlois WJ, Kobayashi M. Molecular cloning of rat SH2-containing inositol phosphatase 2 (SHIP2) and its role in the regulation of insulin signaling. Biochem Biophys Res Commun 1999;260:256-272.
115. Dubois E, Jacoby M, Blockmans M, Pernot E, Schiffmann SN, Foukas LC, Henquin J-C, Vanhaesebroeck B, Erneux C, Schurmans S. Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse. Cell Signal 2012;24:1971-1980.
116. Bertelli DF, Ueno M, Amaral MEC, Toyama MH, Carneiro EM, Marangoni S, Carvalho CRO, Saad MJA, Velloso LA, Boschero AC. Reversal of denervation-induced insulin resistance by SHIP2 protein synthesis blockade. Am J Physiol 2003;284:E679-E687.
117. Buettner R, Ottinger I, Gerhardt-Salbert C, Wrede CE, Schölmerich J, Bollheimer LC. Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome. Am J Physiol 2007;292:E1871-E1878.
118. Tang X, Powelka AM, Soriano NA, Czech MP, Guilherme A. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes. J Biol Chem 2005;280:22523-22529.
119. Gupta A, Dey CS. PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase. Mol Cell Endocrinol 2009;309:55-62.
120. Wada T, Sasaoka T, Funaki M, Hori H, Murakami S, Ishiki M, Haruta T, Asano T, Ogawa W, Ishihara H, Kobayashi M. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity. Mol Cell Biol 2001;21:1633-1646.
121. Sasaoka T, Hori H, Wada T, Ishiki M, Haruta T, Ishihara H, Kobayashi M. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia 2001;44:1258-1267.
122. Marion E, Kaisaki PJ, Pouillon V, Gueydan C, Levy JC, Bodson A, Krzentowski G, Daubresse J-C, Mockel J, Behrends J, Servais G, Szpirer C, Kruys V, Gauguier D, Schurmans S. The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 2002;51:2012-2017.
123. Hori H, Sasaoka T, Ishihara H, Wada T, Murakami S, Ishiki M, Kobayashi M. Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 2002;51:2387-2394.
124. Ishida S, Funakoshi A, Miyasaka K, Shimokata H, Ando F, Takiguchi S. Association of SH-2 containing inositol 5′-phosphatase 2 gene polymorphisms and hyperglycemia. Pancreas 2006;33:63-67.
125. Kagawa S, Sasaoka T, Yaguchi S, Ishihara H, Tsuneki H, Murakami S, Fukui K, Wada T, Kobayashi S, Kimura I, Kobayashi M. Impact of Src homology 2-containing inositol 5′-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling. J Clin Endocrinol Metab 2005;90:2911-2919.
126. Kaisaki PJ, Delepine M, Peng YW, Sebag-Montefiore L, Wilder SP, Menzel S, Vionnet N, Marion E, Riveline J-P, Charpentier G, Schurmans S, Levy JC, Lathrop M, Farrall M, Gauguier D. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes 2004;53:1900-1904.
127. DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ. APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt pathway via the phosphoinositol phosphatase SHIP2. Circ Res 2006;99:829-836.
128. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303.
129. Muraille E, Dassesse D, Vanderwinden JM, Cremer H, Rogister B, Erneux C, Schiffmann SN. The SH2 domain-containing 5-phosphatase SHIP2 is expressed in the germinal layers of embryo and adult mouse brain: Increased expression in N-CAM-deficient mice. Neuroscience 2001;105:1019-1030.
130. Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-1338.
131. Jiang H, Guo W, Liang X, Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: Critical roles of GSK-3β and its upstream regulators. Cell 2005;120:123-135.
132. Aoki K, Nakamura T, Inoue T, Meyer T, Matsuda M. An essential role for the SHIP2-dependent negative feedback loop in neuritogenesis of nerve growth factor-stimulated PC12 cells. J Cell Biol 2007;177:817-827.
133. Hakim S, Bertucci MC, Conduit SE, Vuong DL, Mitchell CA. Inositol polyphosphate phosphatases in human disease. Curr Top Microbiol Immunol 2012;362:247-314.
134. Zhang Q, Claret FX. Phosphatases: The new brakes for cancer development? Enzyme Res 2012;2012:659649.
135. Yang L, Williams DE, Mui A, Ong C, Krystal G, Van Soest R, Andersen RJ. Synthesis of pelorol and analogues: Activators of the inositol 5-phosphatase SHIP. Org Lett 2005;7:1073-1076.
136. Goclik E, König GM, Wright AD, Kaminsky R. Pelorol from the tropical marine sponge Dactylospongia elegans. J Nat Prod 2000;63:1150-1152.
137. Kwak JH, Schmitz FJ, Kelly M. Sesquiterpene quinols/quinones from the Micronesian sponge Petrosaspongia metachromia. J Nat Prod 2000;63:1153-1156.
138. Meimetis LG, Nodwell M, Yang L, Wang X, Wu J, Harwig C, Stenton GR, MacKenzie LF, MacRury T, Patrick BO, Ming-Lum A, Ong CJ, Krystal G, Mui ALF, Andersen RJ. Synthesis of SHIP1-activating analogs of the sponge meroterpenoid pelorol. Eur J Org Chem 2012;2012:5195-5207.
139. Ong CJ, Ming-Lum A, Nodwell M, Ghanipour A, Yang L, Williams DE, Kim J, Demirjian L, Qasimi P, Ruschmann J, Cao LP, Ma K, Chung SW, Duronio V, Anderson RJ, Krystal G, Mui AL. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 2007;110:1942-1949.
140. Mackenzie L, Macrury T, Harwig C, Khlebnikov V, Shan R, Place S, Bird P, Pettigrew J, Bhatti NA. SHIP1 modulators and methods related thereto. Patent Appl. 2011; WO 2011069118.
141. Stenton GR, MacKenzie LF, Tam P, Cross JL, Harwig C, Raymond J, Toews J, Wu J, Ogden N, MacRury T, Szabo C. Characterization of AQX-1125, a small-molecule SHIP1 activator. Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol 2013;168:1506-1518.
142. Stenton GR, Mackenzie LF, Tam P, Cross JL, Harwig C, Raymond J, Toews J, Chernoff D, MacRury T, Szabo C. Characterization of AQX-1125, a small-molecule SHIP1 activator. Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol 2013;168:1519-1529.
143. Shen Y, Burgoyne DL. Efficient synthesis of IPL576, 092: A novel anti-asthma agent. J Org Chem 2002;67:3908-3910.
144. Williams DE, Amlani A, Dewi AS, Patrick BO, van Ofwegen L, Mui ALF, Andersen RJ. Australin E isolated from the soft coral Cladiella sp. collected in pohnpei activates the inositol 5-phosphatase SHIP1. Aust J Chem 2010;63:895-900.
145. Li D, Carr G, Zhang Y, Williams DE, Amlani A, Bottriell H, Mui ALF, Andersen RJ. Turnagainolides A and B, cyclic depsipeptides produced in culture by a Bacillus sp.: Isolation, structure elucidation, and synthesis. J Nat Prod 2011;74:1093-1099.
146. 2+ responses in rat hepatocytes. FASEB J 2007;21:1481-1491.
147. Sasaoka T, Wada T, Fukui K, Murakami S, Ishihara H, Suzuki R, Tobe K, Kadowaki T, Kobayashi M. SH2-containing inositol phosphatase 2 predominantly regulates Akt2, and not Akt1, phosphorylation at the plasma membrane in response to insulin in 3T3-L1 adipocytes. J Biol Chem 2004;279:14835-14843.
148. Suwa A, Kurama T, Yamamoto T, Sawada A, Shimokawa T, Aramori I. Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes. Eur J Pharmacol 2010;642:177-182.
149. Ichihara Y, Fujimura R, Tsuneki H, Wada T, Okamoto K, Gouda H, Hirono S, Sugimoto K, Matsuya Y, Sasaoka T, Toyooka N. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2). Eur J Med Chem 2013;62:649-660.
150. Mills SJ, Persson C, Cozier G, Thomas MP, Tresaugues L, Erneux C, Riley AM, Nordlund P, Potter BVL. A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery. ACS Chem Biol 2012;7:822-828.
151. Annis DA, Cheng CC, Chuang C-C, McCarter JD, Nash HM, Nazef N, Rowe T, Kurzeja RJM, Shipps GW, Jr. Inhibitors of the lipid phosphatase SHIP2 discovered by high throughput affinity selection-mass spectrometry screening of combinatorial libraries. Comb Chem High Throughput Screen 2009;12:760-771.
152. Rowe T, Hale C, Zhou A, Kurzeja RJM, Ali A, Menjares A, Wang M, McCarter JD. A High-throughput microfluidic assay for SH2 domain-containing inositol 5-phosphatase 2. Assay Drug Dev Technol 2006;4:175-183.
153. Kim J-S, Yun HS, Um H-D, Park JK, Lee K-H, Kang C-M, Lee S-J, Hwang S-G. Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biol Ther 2012;13:1307-1318.
154. Bertucci MC, Mitchell CA. Phosphoinositide 3-kinase and INPP4B in human breast cancer. Ann NY Acad Sci 2013;1280:1-5.